Lineage Cell Therapeutics Inc (LCTX) — Long-term Investment Intensity

Latest as of June 2019: 39.2%

Lineage Cell Therapeutics Inc (LCTX) has a Long-term Investment Intensity of 39.2% as of June 2019. Long-term investments of $59.40 Million represent 39.2% of total assets of $151.69 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See LCTX net assets for net asset value and shareholders' equity analysis.

LT Investment Intensity

39.2%
LT Investments / Total Assets

Long-term Investments

$59.40 Million
USD

Total Assets

$151.69 Million
USD

Country

USA
NYSE MKT

Lineage Cell Therapeutics Inc Long-term Investment Intensity (2015–2018)

This chart shows how Lineage Cell Therapeutics Inc's Long-term Investment Intensity has evolved across 4 annual periods from 2015 to 2018. As of June 2019, the intensity stands at 39.2%, reflecting long-term investments of $59.40 Million against total assets of $151.69 Million USD. Also explore Lineage Cell Therapeutics Inc asset portfolio for the complete picture of this company's asset base.

Annual Long-term Investment Intensity for Lineage Cell Therapeutics Inc (2015–2018)

The table below presents the year-by-year Long-term Investment Intensity for Lineage Cell Therapeutics Inc from 2015 to 2018, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Lineage Cell Therapeutics Inc stock valuation.

Year LT Investment Intensity LT Investments (USD) Total Assets Change (pp)
2018 54.9% $55.84 Million $101.66 Million ▼ -12.7 pp
2017 67.6% $117.17 Million $173.24 Million ▼ -2.5 pp
2016 70.2% $100.04 Million $142.57 Million ▲ +65.2 pp
2015 4.9% $4.67 Million $94.66 Million
pp = percentage points